MedPath
HSA Approval

DAPRIL 5 TABLET 5 mg

SIN11994P

DAPRIL 5 TABLET 5 mg

DAPRIL 5 TABLET 5 mg

June 24, 2002

MEDOCHEMIE SINGAPORE PTE. LTD.

MEDOCHEMIE SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantMEDOCHEMIE SINGAPORE PTE. LTD.
Licence HolderMEDOCHEMIE SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C09AA03

lisinopril

Manufacturer Information

MEDOCHEMIE SINGAPORE PTE. LTD.

MEDOCHEMIE LTD - CENTRAL FACTORY

MEDOCHEMIE LTD -FACTORY AZ (Primary & Secondary Packager)

Active Ingredients

LISINOPRIL DIHYDRATE EQV LISINOPRIL

5 mg

Lisinopril

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DAPRIL 5 TABLET 5 mg - HSA Approval | MedPath